Tumor Venéreo Transmisible Nasal (TVTN) en canino de raza Pinscher.

Abstract

The Transmissible Venereal Tumor is a common neoplasm that affects dogs of different ages and breeds, especially those that are in street condition and that are may be in contact with the neoplasm present in another canine. This tumor has different forms of presentation forms depending on the place where the contact is present. In this report, we describe clinical case of a 6-year-old pinscher breed patient who shows signs such as decay, epistaxis, sneezing with an increased nasal volume. At the clinical examination, the patient presents with nasal snoring, apyrexy, ectoparasites and when palpating the increased nasal area, it had a soft consistency and was full of liquid. A puncture is made extracting fresh blood and it is completely drained, however filling again in few minutes. It is recommended to perform hematology, blood chemistry Alanine aminotransferase (ALT), Creatinine (CREA), cytology, x-rays. However, the owner only accepts going through with hematology and blood chemistry. At the hematology the main findings were normochromic normocytic anemia, neutropenia, lymphocytosis, leukocytosis and marked thrombocytopenia. At the blood chemistry, ALT and CREA parameters were within the normal ranges and the patient is decided to be sent home with treatment for hemoparasites and control for August 15. The patient then, returns on August 23 with dyspnea and, with increased nasal volume, this time the area is only drained as per owner’s decision and the sent home again. On September 20th, the dog again to perform cytology, results report round cells compatible with transmissible venereal tumor, while the x-rays showed no bone deformation and no compromise of anatomical structures. Blood tests and blood chemistry tests are repeated to start the treatment since the previous tests were outside the normal ranges. The results were satisfactory since they were within the reference parameters. For the treatment, intravenous therapy was established using the chemotherapy drug Vincristine sulfate at 0.5mg/m2 dose weekly for 4 consecutive weeks. Finding evolution of the signs from the first dose, and total remission by the fourth dose.